Trials / Completed
CompletedNCT03407599
A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 6 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The study is done to compare how faster aspart is taken up, broken down and removed from the body between different age groups (children \[6-11 years\], adolescents \[12-17 years\] and adults \[18-64 years\]) who have diabetes. The blood sugar (glucose) lowering effect of faster aspart will also be investigated after consuming a meal replacement drink. The effects of faster aspart will be compared to the effects of NovoRapid®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Faster aspart | An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal. |
| DRUG | Insulin aspart (NovoRapid®) | An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal. |
Timeline
- Start date
- 2018-01-08
- Primary completion
- 2018-07-05
- Completion
- 2018-07-05
- First posted
- 2018-01-23
- Last updated
- 2019-06-19
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03407599. Inclusion in this directory is not an endorsement.